DiaMedica Therapeutics, Inc.
DiaMedica-Logo
Navigate DiaMedica Therapeutics, Inc.
Home
About Us
Company Overview
Leadership Team
Board of Directors
Clinical Advisory Boards
Science
Our Science
Pipeline
Diseases We Target
Overview
IgA Nephropathy
African Americans - Hypertensive with CKD
Acute Ischemic Stroke
Investors & Media
Investors Home
Press Releases
Events & Presentations
Nasdaq Stock Information
Analyst Coverage
Financial Reports
Governance
Investor Resources
Careers
Contact
Home
News
News
All News
By Year:
2020
2019
2018
2017
2016
May 6, 2019
DiaMedica Therapeutics to Report First Quarter 2019 Financials and Provide an Update on Development Programs on May 14, 2019
Apr 30, 2019
DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
Mar 19, 2019
DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update
Mar 18, 2019
DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
Mar 12, 2019
DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
Feb 14, 2019
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
Jan 22, 2019
DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
Jan 9, 2019
DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
Jan 3, 2019
DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
Dec 7, 2018
DiaMedica Announces Pricing of Initial Public Offering and Nasdaq Listing
« Previous
1
2
3
4
5
6
7
8
Next »